How to mislead the public: a case study in apparent naivety

An article in today’s Daily Telegraph in the UK starts with the misleading statement that, “Up to half of men diagnosed with prostate cancer are being given ‘false hope’ by tests that are underestimating the severity of their disease, according to the authors of a new study.” … READ MORE …

Does cannabis have value in the management of prostate cancer?

If you do a PubMed search for “cannabis + prostate + cancer” you will find remarkably few articles that deal specifically with the impact of cannabis use and its relationship to prostate cancer — either in a positive or a negative sense. … READ MORE …

What’s being presented at the AUA in May: Part III

In the “Outstanding Posters” sessions at the annual meeting of the American Urological Association meeting upcoming in Orlando, there are several posters that deal specifically with prostate cancer-related issues. … READ MORE …

“Best care” doesn’t equate to better outcomes! That’s not good!

A poster by Schroeck et al. — to be presented on May 20 at the upcoming annual meeting of the American Urological Association (AUA) — presents the latest set of data suggesting that “best care” does not lead to appropriate outcomes quality for men receiving standard forms of treatment for localized prostate cancer. … READ MORE …

What’s being presented at the AUA in May: Part II

Here is information about more papers being presented at the annual meeting on the American Urological Association annual meeting in May. … READ MORE …

What’s being presented at the AUA in May: Part I

This is the first of several summary posts commenting briefly on new data to be presented at the annual meeting of the American Urological Association (AUA) this year. Individual presentations of important new data will be separately addressed … READ MORE …

Is AR-V7-positive status a contraindication to enzalutamide therapy?

According to a media release issued by the American Association for Cancer Research (AACR), it may be possible to identify some men with advanced prostate cancer who are highly likely to be resistant to treatment with enzalutamide. … READ MORE …

The potential of metformin in prostate cancer treatment: an update

We have previously commented (more than once) on the perception that metformin may have some value in the management of prostate cancer. A recently reported (albeit small), prospective Swiss study, has added to our knowledge in this regard. … READ MORE …

Medivation/Astellas seek expanded indication for enzalutamide in Europe

According to a media release this morning from Medivation and Astellas Pharma, the companies have completed submission of data in support of the expansion of the European Marketing Authorization for enzalutamide — to include men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

New Phase I/II trial of InSightec’s MRI-guided focal ultrasound therapy

According to a media release issued yesterday by the City of Hope medical center in Los Angeles, they have become the first center in the USA to treat a patient with focused, MRI-guided, ultrasound technology using the InSightec system. … READ MORE …

Cialis doesn’t help to maintain erectile function among radiotherapy patients

The degree to which drugs like sildenafil (Viagra) and taldalafil (Cialis) may help patient to maintain erectile function after treatment for localized prostate cancer has long been open to question. … READ MORE …

Gleason score and metastatic prostate cancer; risk for 4-year mortality

It is difficult to accurately interpret a set of data just published that was designed to assess the relationship between 4-year survival and Gleason score at diagnosis in men initially diagnosed with metastatic prostate cancer. … READ MORE …

Focal therapy for organ-confined prostate cancer: an expert overview

For those who are interested in the current state of focal therapy in the management of localized, organ-confined prostate cancer, there is a nice audio overview by Dr. James Eastham of the Memorial Sloan-Kettering Cancer Center on the UroToday web site. … READ MORE …

Who decides the “value” of a new cancer drug — and how?

In an interesting wrinkle that may profoundly impact the drug pricing debate here in America, the American Society for Clinical Oncology (ASCO) has decided to “score” the value of new cancer drugs as they are brought to market. … READ MORE …

COMET-1 trial does not show survival benefit … yet

Some in the investment community (and probably many in Exelixis itself) had been hoping that an interim analysis of an ongoing Phase III trial of cabozantinib (Cometriq) in the treatment of late-stage prostate cancer would show a positive outcome and allow the trial to be stopped early. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers